-->
17-alpha hydroxyprogesterone (17P) may reduce preterm deliveries, but it doesn't seem to reduce perinatal deaths. At least that's the conclusion of a large study reported at this year's Annual Clinical Meeting. To reach that conclusion, University of Miami investigators examined a database of high-risk patients with prior preterm deliveries (PTD) (n=699) and current singleton gestations who had been receiving weekly 250 mg IM injections of 17P, or observation (n=880). While those on progesterone delivered at 36.2 weeks (+/- 4.2), compared to 35.5 weeks ( +/- 4.2) (P<0.001), there were no significant differences between the groups when researchers looked at the incidence of stillbirths, neonatal deaths, miscarriages at less than 24 weeks, or total perinatal deaths.
Gonzalez-Quentero VH, Smarkusky L, Carter J, et al. 17-alpha-hydroxyprogesterone caproate: perinatal mortality and pregnancy outcomes. Obstet Gynecol. 2007;109(suppl):7S.
Get the latest clinical updates, case studies, and expert commentary in obstetric and gynecologic care. Sign up now to stay informed.
Trimethoprim–sulfamethoxazole not found to increase infant birth weight in HIV cases
July 9th 2025A recent randomized trial found no significant improvement in birth weight or key birth outcomes from antenatal trimethoprim–sulfamethoxazole prophylaxis in human immunodeficiency virus-positive pregnant women.
Read More